523 related articles for article (PubMed ID: 18271296)
1. Identification, isolation, synthesis and characterization of impurities of quetiapine fumarate.
Bharathi Ch; Prabahar KJ; Prasad ChS; Srinivasa Rao M; Trinadhachary GN; Handa VK; Dandala R; Naidu A
Pharmazie; 2008 Jan; 63(1):14-9. PubMed ID: 18271296
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of potential impurities of quetiapine fumarate.
Stolarczyk EU; Kaczmarek L; Eksanow K; Kubiszewski M; Glice M; Kutner A
Pharm Dev Technol; 2009; 14(1):27-37. PubMed ID: 18815940
[TBL] [Abstract][Full Text] [Related]
3. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of new impurity in didanosine.
Srinivasa Rao DV; Srinivas N; Bharathi Ch; Prasad ChS; Dandala R; Naidu A
J Pharm Biomed Anal; 2007 Nov; 45(3):516-20. PubMed ID: 17624711
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of some potential impurities in ropinirole hydrochloride.
Sahasrabuddhey B; Nautiyal R; Acharya H; Khyade S; Luthra PK; Deshpande PB
J Pharm Biomed Anal; 2007 Mar; 43(4):1587-93. PubMed ID: 17207602
[TBL] [Abstract][Full Text] [Related]
6. Structural identification and characterization of impurities in ceftizoxime sodium.
Bharathi Ch; Prasad ChS; Bharathi DV; Shankar R; Rao VJ; Dandala R; Naidu A
J Pharm Biomed Anal; 2007 Jan; 43(2):733-40. PubMed ID: 16950586
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of potential impurities of amlodipine maleate.
Sudhakar P; Nirmala M; Moses Babu J; Vyas K; Madhusudan Reddy G; Vijaya Bhaskar B; Pratap Reddy P; Mukkanti K
J Pharm Biomed Anal; 2006 Feb; 40(3):605-13. PubMed ID: 16324814
[TBL] [Abstract][Full Text] [Related]
8. Identification, isolation and characterization of process-related impurities in Rizatriptan benzoate.
Raj TJ; Bharathi Ch; Kumar MS; Prabahar J; Kumar PN; Sharma HK; Parikh K
J Pharm Biomed Anal; 2009 Jan; 49(1):156-62. PubMed ID: 19056198
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of potential impurities of donepezil.
Krishna Reddy KV; Moses Babu J; Kumar PA; Chandrashekar ER; Mathad VT; Eswaraiah S; Reddy MS; Vyas K
J Pharm Biomed Anal; 2004 Sep; 35(5):1047-58. PubMed ID: 15336352
[TBL] [Abstract][Full Text] [Related]
10. Identification, isolation and characterization of potential degradation products in pioglitazone hydrochloride drug substance.
Ramulu K; Kumar TT; Krishna SR; Vasudev R; Kaviraj M; Rao BM; Rao NS
Pharmazie; 2010 Mar; 65(3):162-8. PubMed ID: 20383934
[TBL] [Abstract][Full Text] [Related]
11. Structural identification and characterization of impurities in moxifloxacin.
Kumar YR; Prasad Raju VV; Kumar RR; Eswaraiah S; Mukkanti K; Suryanarayana MV; Reddy MS
J Pharm Biomed Anal; 2004 Mar; 34(5):1125-9. PubMed ID: 15019047
[TBL] [Abstract][Full Text] [Related]
12. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
[TBL] [Abstract][Full Text] [Related]
13. Structural studies of racecadotril and its process impurities by NMR and mass spectroscopy.
Reddy KM; Babu JM; Sudhakar P; Sharma MS; Reddy GS; Vyas K
Pharmazie; 2006 Dec; 61(12):994-8. PubMed ID: 17283655
[TBL] [Abstract][Full Text] [Related]
14. Structural characterization of impurities in pioglitazone.
Kumar YR; Reddy AR; Eswaraiah S; Mukkanti K; Reddy MS; Suryanarayana MV
Pharmazie; 2004 Nov; 59(11):836-9. PubMed ID: 15587582
[TBL] [Abstract][Full Text] [Related]
15. Identification, synthesis, isolation and spectral characterization of potential impurities of montelukast sodium.
Saravanan M; Siva Kumari K; Pratap Reddy P; Naidu MN; Moses Babu J; Srivastava AK; Lakshmi Kumar T; Chandra Sekhar BV; Satyanarayana B
J Pharm Biomed Anal; 2008 Nov; 48(3):708-15. PubMed ID: 18755563
[TBL] [Abstract][Full Text] [Related]
16. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation.
Thomas S; Mathela CS; Agarwal A; Paul SK
J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571
[TBL] [Abstract][Full Text] [Related]
17. Isolation and structural identification of an impurity in fluconazole bulk drug substance.
Dongre VG; Ghugare PD; Karmuse PP; Soudagar SR; Panda N; Kumar A
J Pharm Biomed Anal; 2007 Nov; 45(3):422-9. PubMed ID: 17706390
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of new impurities in rivastigmine.
Srinivasa Rao M; Rao SV; Srinivasa Rao DV; Bharathi Ch; Rajput P; Sharma HK
Pharmazie; 2010 May; 65(5):336-8. PubMed ID: 20503924
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist.
Sampath A; Reddy AR; Yakambaram B; Thirupathi A; Prabhakar M; Reddy PP; Reddy VP
J Pharm Biomed Anal; 2009 Oct; 50(3):405-12. PubMed ID: 19560892
[TBL] [Abstract][Full Text] [Related]
20. Identification, isolation, and characterization of potential degradation products in a triple combination lamivudine, zidovudine, and nevirapine tablet for oral suspension.
Aparna P; Rao SV; Thomas KM; Mukkanti K; Badarinadh Gupta P; Rangarao K; Narayan GK; Sandip T; Upendra K
Pharmazie; 2010 May; 65(5):331-5. PubMed ID: 20503923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
